Clinical Trials
9 trialsNCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT03728361 2025-12-18
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07118176 2025-08-12
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
Phase 1 Recruiting
NCT06937112 2025-04-22
18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
Nanjing First Hospital, Nanjing Medical University
Recruiting
NCT00227617 2023-05-22
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Phase 2/3 Terminated
NCT02817945 2022-04-07
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Unknown
NCT02948946 2021-08-04
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Completed
NCT02030184 2019-10-17
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
University of Maryland, Baltimore
Phase 1/2 Withdrawn
NCT01135849 2015-11-17
B-Receptor Signaling in Cardiomyopathy
Stanford University
Completed